In CLL-11, for the first-line treatment of typical* patients, in combination with Clb
GAZYVA DEMONSTRATED SUPERIOR PFS vs RITUXIMAB1-4
GAZYVA + CLB DELIVERED A SIGNIFICANT IMPROVEMENT IN MEDIAN PFS COMPARED TO RITUXIMAB
+ CLB IN FIRST-LINE CLL (26.7 MONTHS VS 14.9 MONTHS) WITH 6 PLANNED CYCLES OF THERAPY1
Proportion progression free
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
14.9
GAZYVA + Clb (n=333)
rituximab + Clb (n=330)